Comparison of Carboplatin and Doxorubicin-based Chemotherapy Protocols in 470 Dogs After Amputation for Treatment of Appendicular Osteosarcoma

Overview

Journal J Vet Intern Med

Specialties General Medicine
Veterinary Medicine

Date 2014 Feb 12

PMID 24512451

Citations 70

Authors

L E Selmic

J H Burton

D H Thamm

S J Withrow

S E Lana

Affiliations

Soon will be listed here.

Abstract

Background: Many chemotherapy protocols have been reported for treatment of canine appendicular osteosarcoma (OSA), but outcome comparisons in a single population are lacking.

Objective: To evaluate the effects of protocol and dose intensity (DI) on treatment outcomes for carboplatin and doxorubicin-based chemotherapy protocols.

Animals: Four hundred and seventy dogs with appendicular OSA.

Methods: A retrospective cohort study was performed comprising consecutive dogs treated (1997-2012) with amputation followed by 1 of 5 chemotherapy protocols: carboplatin 300 mg/m(2) IV q21d for 4 or 6 cycles (CARBO6), doxorubicin 30 mg/m(2) IV q14d or q21d for 5 cycles, and alternating carboplatin 300 mg/m(2) IV and doxorubicin 30 mg/m(2) IV q21d for 3 cycles. Adverse events (AE) and DI were evaluated. Kaplan-Meier survival curves and Cox proportional hazards regression were used to compare disease-free interval (DFI) and survival time (ST) among protocols.

Results: The overall median DFI and ST were 291 days and 284 days, respectively. A lower proportion of dogs prescribed CARBO6 experienced AEs compared to other protocols (48.4% versus 60.8-75.8%; P = .001). DI was not associated with development of metastases or death. After adjustment for baseline characteristics and prognostic factors, none of the protocols provided a significant reduction in risk of development of metastases or death.

Conclusions And Clinical Importance: Although choice of protocol did not result in significant differences in DFI or ST, the CARBO6 protocol resulted in a lower proportion of dogs experiencing AEs, which could be advantageous in maintaining high quality of life during treatment. DI was not a prognostic indicator in this study.

Citing Articles

Limb-Sparing Surgery and Stifle Arthrodesis Using Patient-Specific 3D-Printed Guides and Endoprosthesis for Distal Femoral Chondrosarcoma in a Dog: A Case Report.

Panichi E, Tabbi M, Principato G, Dal Magro V, Valentini F, Currenti M Animals (Basel). 2025; 15(5).

PMID: 40075956 PMC: 11898944. DOI: 10.3390/ani15050673.

Plasma microRNA signatures predict prognosis in canine osteosarcoma patients.

Ludwig L, Edson M, Treleaven H, Viloria-Petit A, Mutsaers A, Moorehead R PLoS One. 2024; 19(12):e0311104.

PMID: 39739708 PMC: 11687810. DOI: 10.1371/journal.pone.0311104.

Comparative responses to demethylating therapy in animal models of osteosarcoma.

Huang S, Ren L, Beck J, Patkar S, Lillo Osuna M, Cherukuri A Res Sq. 2024; .

PMID: 38946977 PMC: 11213205. DOI: 10.21203/rs.3.rs-4451060/v1.

Clinical, pathologic and molecular findings in 2 Rottweiler littermates with appendicular osteosarcoma.

Silver K, Mannheimer J, Saba C, Hendricks W, Wang G, Day K Res Sq. 2024; .

PMID: 38659878 PMC: 11042397. DOI: 10.21203/rs.3.rs-4223759/v1.

Bringing the Genomic Revolution to Comparative Oncology: Human and Dog Cancers.

Cahill J, Smith L, Gottipati S, Torabi T, Graim K Annu Rev Biomed Data Sci. 2024; 7(1):107-129.

PMID: 38648188 PMC: 11343685. DOI: 10.1146/annurev-biodatasci-102423-111936.

References

Frei 3rd E, Elias A, Wheeler C, Richardson P, Hryniuk W . The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Clin Cancer Res. 1998; 4(9):2027-37. View

Kawai A, Sugihara S, Kunisada T, Hamada M, Inoue H . The importance of doxorubicin and methotrexate dose intensity in the chemotherapy of osteosarcoma. Arch Orthop Trauma Surg. 1996; 115(2):68-70. DOI: 10.1007/BF00573443. View

Chun R, Garrett L, Henry C, Wall M, Smith A, Azene N . Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. J Am Anim Hosp Assoc. 2005; 41(6):382-7. DOI: 10.5326/0410382. View

Choeyprasert W, Natesirinilkul R, Charoenkwan P, Sittipreechacharn S . Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand. Asian Pac J Cancer Prev. 2013; 14(2):1101-6. DOI: 10.7314/apjcp.2013.14.2.1101. View

Phillips B, Powers B, Dernell W, Straw R, Khanna C, Hogge G . Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs. J Am Anim Hosp Assoc. 2009; 45(1):33-8. DOI: 10.5326/0450033. View

Kraegel S, Madewell B, SIMONSON E, Gregory C . Osteogenic sarcoma and cisplatin chemotherapy in dogs: 16 cases (1986-1989). J Am Vet Med Assoc. 1991; 199(8):1057-9. View

Moore A, Dernell W, Ogilvie G, Kristal O, Elmslie R, Kitchell B . Doxorubicin and BAY 12-9566 for the treatment of osteosarcoma in dogs: a randomized, double-blind, placebo-controlled study. J Vet Intern Med. 2007; 21(4):783-90. DOI: 10.1892/0891-6640(2007)21[783:dabftt]2.0.co;2. View

Lascelles B, Dernell W, Correa M, Lafferty M, Devitt C, Kuntz C . Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma. Ann Surg Oncol. 2005; 12(12):1073-83. DOI: 10.1245/ASO.2005.01.011. View

Boerman I, Selvarajah G, Nielen M, Kirpensteijn J . Prognostic factors in canine appendicular osteosarcoma - a meta-analysis. BMC Vet Res. 2012; 8:56. PMC: 3482154. DOI: 10.1186/1746-6148-8-56. View

10.

Liptak J, Dernell W, Straw R, Rizzo S, Lafferty M, Withrow S . Proximal radial and distal humeral osteosarcoma in 12 dogs. J Am Anim Hosp Assoc. 2004; 40(6):461-7. DOI: 10.5326/0400461. View

11.

Delepine N, Delepine G, Bacci G, Rosen G, Desbois J . Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature. Cancer. 1996; 78(10):2127-35. View

12.

Straw R, Withrow S, Richter S, Powers B, Klein M, Postorino N . Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med. 1991; 5(4):205-10. DOI: 10.1111/j.1939-1676.1991.tb00950.x. View

13.

Chun R, Kurzman I, Couto C, Klausner J, Henry C, MacEwen E . Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: a pilot study. J Vet Intern Med. 2000; 14(5):495-8. DOI: 10.1892/0891-6640(2000)014<0495:cadccf>2.3.co;2. View

14.

Bacci G, Ferrari S, Longhi A, Forni C, Giacomini S, Lari S . Relationship between dose-intensity of treatment and outcome for patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Oncol Rep. 2001; 8(4):883-8. DOI: 10.3892/or.8.4.883. View

15.

Berg J, Gebhardt M, Rand W . Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma. Cancer. 1997; 79(7):1343-50. View

16.

Hagleitner M, de Bont E, Loo D . Survival trends and long-term toxicity in pediatric patients with osteosarcoma. Sarcoma. 2012; 2012:636405. PMC: 3512330. DOI: 10.1155/2012/636405. View

17.

Straw R, Withrow S, Powers B . Management of canine appendicular osteosarcoma. Vet Clin North Am Small Anim Pract. 1990; 20(4):1141-61. DOI: 10.1016/s0195-5616(90)50089-3. View

18.

Lewis I, Weeden S, Machin D, Stark D, Craft A . Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup. J Clin Oncol. 2000; 18(24):4028-37. DOI: 10.1200/JCO.2000.18.24.4028. View

19.

Mauldin G, Matus R, Withrow S, Patnaik A . Canine osteosarcoma. Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Intern Med. 1988; 2(4):177-80. DOI: 10.1111/j.1939-1676.1988.tb00313.x. View

20.

Thompson J, Fugent M . Evaluation of survival times after limb amputation, with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979-1990). J Am Vet Med Assoc. 1992; 200(4):531-3. View